Thu, Jan 29, 2015, 6:17 AM EST - U.S. Markets open in 3 hrs 13 mins

Recent

% | $
Quotes you view appear here for quick access.

Somaxon Pharmaceuticals, Inc. Message Board

dctrig 57 posts  |  Last Activity: Jan 26, 2015 1:39 PM Member since: Jan 26, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • ETRM has total discretion when and if to use the ATM. No responsible CEO and board of directors would sell shares prematurely at a near yearly low when immediate cash is NOT NEEDED.

  • Reply to

    UCLA Surgeon's Excellent & Balanced Review of VBLOC

    by dctrig Jan 22, 2015 4:30 PM
    dctrig dctrig Jan 22, 2015 8:08 PM Flag

    These are two other unbiased opinions published in WSJ)
    John Alverdy, a gastrointestinal surgeon at the University of Chicago who isn’t connected to the company, said the device is an early version of the technology, and that treating doctors may be able to make it more effective by tinkering with how it is used. The lasting power of the treatment isn’t clear, he said.
    Philip Schauer, director of the Cleveland Clinic’s bariatric and metabolic institute, said the device’s effect “is fairly modest compared to gastric banding and gastric bypass, but far exceeds any type of diet or drug therapy.” He isn't connected to EnteroMedics.

  • Reply to

    UCLA Surgeon's Excellent & Balanced Review of VBLOC

    by dctrig Jan 22, 2015 4:30 PM
    dctrig dctrig Jan 22, 2015 6:37 PM Flag

    Ade: This makes the third surgeon from a major medical facility who has commented favorably on VBLOC. The others are from Univ of Chicago and the Cleveland Clinic. Their comment can be accessed thru Barrons website then ETRM quote page, then WSJ story(despite what it says you don't need to be a subscriber to read).

  • Reply to

    UCLA Surgeon's Excellent & Balanced Review of VBLOC

    by dctrig Jan 22, 2015 4:30 PM
    dctrig dctrig Jan 22, 2015 4:39 PM Flag

    Curiously Dr Greer only comments favorably on the 12-month sustained weight loss; however, ETRM has 18-24 month data showing continuing weight loss.

  • To see the video go to Marketwatch and punch in ETRM. In the comments ection is a link to Healthcare Channel and Dr Greer's presentation.

  • Reply to

    Just my Guess

    by innsbrooklad Jan 21, 2015 3:58 PM
    dctrig dctrig Jan 21, 2015 4:40 PM Flag

    Inns: It would make no sense to utilize the Cowen ATM at fire-sale prices. This is a computer-traded walk down. Trading desks prey on the general market as witness many biotechs under attack today. This is 2015 and the trading algorithms and hedge strategies make a mockery of an honest and orderly market.

  • Reply to

    Mentality

    by stockforlong Jan 21, 2015 1:02 PM
    dctrig dctrig Jan 21, 2015 1:49 PM Flag

    The "WHO" are trading algorithms, not actual individuals. If you carefully observe most trading days in the stock market follow a stereotypical pattern of an early jump, sharp pullback and then a price pickup near the close. High frequency trading desks care ZILCH about the value of a company. When some HFT desks have 90% or more profitable trading days in a year you know the system is rigged.
    Smart individual traders load up on unfairly beaten down stocks.

  • dctrig dctrig Jan 20, 2015 11:51 AM Flag

    Kaiser Pemanente is the worst example of health care rationing. I'm one of their members and my internist refuses to recommend a hernia operation, PSA test, digital prostate exam. I had to twist his arm for a shingle vaccination. My general ophthalmologist resists referring me to a retinal specialist, despite my prior vision issues and won't take basic retina pictures.
    Gold plate plans WILL cover VBLOC in the next 12-18 months.

  • Reply to

    ETRM--------- IS GOLD.....in every way

    by nadagold52 Jan 17, 2015 11:42 PM
    dctrig dctrig Jan 19, 2015 12:57 AM Flag

    Christopher Ochner, an obesity and nutrition expert at The Mount Sinai Hospital in New York, said the device's approval is a "positive step."
    "The vagal nerve, on which this system is designed to impart electrical impulses, is quite important in regulating communication along the gut-brain axis," he said.
    "We have come to realize just how vital the neurohormonal system is to the regulation of food intake and body weight, and therapies that alter signaling within this system are almost certainly the wave of the future."

    Sentiment: Strong Buy

  • Reply to

    Reality

    by innsbrooklad Jan 16, 2015 4:15 PM
    dctrig dctrig Jan 16, 2015 6:17 PM Flag

    Innsbrooklad: The smart money bought with both fists today, confirmed by Barrons accumulation figures. A 39% haircut from post approval high of 2.05 is ludicrous and a 52.8% plunge from 52-week high of 2.65, BEFORE we had approval defies common sense. The FDA approval will be a big deal in the rest of world and ETRM is awaiting a third CE mark for hypertension.

  • Reply to

    Patient Manuel is a good read (Link)

    by sharkzfanz Jan 16, 2015 3:31 PM
    dctrig dctrig Jan 16, 2015 3:50 PM Flag

    Not only you. Barrons has shown ETRM under accumulation for the last three days. Imagine the hate PCYC was getting on Yahoo on Aug 1, 2009, when it hit a $1.16 low. Could anyone have predicted it would now be selling for $145?

  • dctrig dctrig Jan 16, 2015 12:15 PM Flag

    Right now the overall market is in turmoil and small and micro caps are almost universally being punished. Today is options expiration day and the market is closed on Monday. ETRM bargain hunters would be wise to load up today before inevitable partnership news is announced. The FDA approval is the gold standard event that many potential partners and doctors were looking for.

  • dctrig dctrig Jan 15, 2015 3:24 PM Flag

    Nearly all small companies that created their own sales and marketing force on a go it alone basis have had dismal sales. A large company like Medtronics has deep and longstanding relationships with tens of thousands of doctors that can't ever be duplicated by a start up sales force, especially with many doctors, medical groups and hospitals severely limiting sales rep access. I recently took a friend to a doctor appt with a hematologist in the West San Fernando Valley of Los Angeles. A sales rep, known to the office receptionist, could not get a 5-minute appt with the doctor until April, despite trying every trick in the book. Creating an independent sales force would be an exercise in futility for ETRM.

  • Reply to

    Wall Street Journal Made Some Good Points

    by dctrig Jan 15, 2015 2:16 PM
    dctrig dctrig Jan 15, 2015 3:11 PM Flag

    (These experts, not connected to ETRM, make great points)

    John Alverdy, a gastrointestinal surgeon at the University of Chicago who isn’t connected to the company, said the device is an early version of the technology, and that treating doctors may be able to make it more effective by tinkering with how it is used. The lasting power of the treatment isn’t clear, he said.
    Philip Schauer, director of the Cleveland Clinic’s bariatric and metabolic institute, said the device’s effect “is fairly modest compared to gastric banding and gastric bypass, but far exceeds any type of diet or drug therapy.” He isn't connected to EnteroMedics.

    . .

  • Federal regulators on Wednesday approved a novel dieting device that acts like a pacemaker for the stomach by manipulating the nerve pathway that makes people feel hungry or full.
    The device, made by EnteroMedics Inc. of St. Paul, Minn., is the first of its kind to treat obesity by targeting nerves that link the stomach and the brain. The Maestro Rechargeable System would block electrical signals in the abdominal vagus nerve by dispatching high-frequency electrical pulses.
    Federally approved weight-loss drugs and devices have huge sales potential but a mixed track record of success. A Food and Drug Administration advisory panel concluded the Maestro system showed a sustained weight loss in patients even though it fell short of its goal.
    John Alverdy, a gastrointestinal surgeon at the University of Chicago who isn’t connected to the company, said the device is an early version of the technology, and that treating doctors may be able to make it more effective by tinkering with how it is used. The lasting power of the treatment isn’t clear, he said.
    Philip Schauer, director of the Cleveland Clinic’s bariatric and metabolic institute, said the device’s effect “is fairly modest compared to gastric banding and gastric bypass, but far exceeds any type of diet or drug therapy.” He isn't connected to EnteroMedics.

  • Reply to

    Definetly options traders

    by dstiestalabombe Jan 15, 2015 1:44 PM
    dctrig dctrig Jan 15, 2015 2:10 PM Flag

    The options market wags the tail of the stock market and gives it direction.

  • Reply to

    Is anyone concerned about further diulution?

    by bmfarrell01 Jan 15, 2015 11:30 AM
    dctrig dctrig Jan 15, 2015 11:39 AM Flag

    No. ETRM will gain one or more deep pocketed partners in the US and rest of world. That's why yesterday they were guarded in explaining their financing plans.

  • Reply to

    1/17 Options Roadblock to Price Gain

    by dctrig Jan 15, 2015 11:07 AM
    dctrig dctrig Jan 15, 2015 11:35 AM Flag

    The market is giving new buyers a huge discount today. Next week 1.30 will look like a huge bargain.

  • The options market wants the 1,939 $2 call options to expire worthless on Friday. Monday should see the start of an upward price movement. The approval IS getting a lot of publicity. KTLA in Los Angeles had a news segment last night and I'm sure others did. ETRM has already updated their website to reflect the FDA approval. I did jump back in yesterday, 14k shares around 1.39.

  • Reply to

    CVEO Will Do What Major Hotel Chains Do

    by dctrig Jan 2, 2015 5:55 PM
    dctrig dctrig Jan 2, 2015 8:40 PM Flag

    North America is the most stable geo political place on earth, a tremendous advantage in time of world crisis. The lodges will have a monopoly when the market recovers as no new ones will be built. It amazes me that people like you are always looking for outsized gains with an ironclad guarantee.

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Facebook, Inc.
NASDAQWed, Jan 28, 2015 4:00 PM EST
Nokia Corporation
NYSEWed, Jan 28, 2015 4:01 PM EST